{"id":390715,"date":"2018-03-29T00:00:00","date_gmt":"2018-03-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0039-2018-biopharma-psoriatic-arthritis-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-15T09:56:38","modified_gmt":"2026-04-15T09:56:38","slug":"algoim0039-2018-biopharma-psoriatic-arthritis-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0039-2018-biopharma-psoriatic-arthritis-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Psoriatic Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>MARKET OUTLOOK<\/p>\n<p>Treatment for\u00a0<abbr data-original-title=\"psoriatic arthritis\" title=\"\">PsA<\/abbr>\u00a0typically begins with a\u00a0<abbr data-original-title=\"conventional disease-modifying antirheumatic drug\" title=\"\">cDMARD<\/abbr>, but often progresses to a\u00a0<abbr data-original-title=\"targeted synthetic disease-modifying antirheumatic drug\" title=\"\">tsDMARD<\/abbr>\u00a0or\u00a0<abbr data-original-title=\"biologic disease-modifying antirheumatic drug\" title=\"\">bDMARD<\/abbr>\u00a0within two years.\u00a0<abbr data-original-title=\"tumor necrosis factor-alpha inhibitor\" title=\"\">TNFi<\/abbr>\u00a0are the mainstay of treatment for recently treated patients, but newer therapies including two\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors have a growing market share. Persistency and compliance are highest for Remicade, but Enbrel and Humira continue to capture the largest portion of the\u00a0<abbr data-original-title=\"biologic disease-modifying antirheumatic drug\" title=\"\">bDMARD<\/abbr>\u00a0market.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How long do patients wait between a diagnosis and an initial prescription? How fast do newly diagnosed patients progress through lines of therapy?<\/li>\n<li>Where in the treatment algorithm will new therapies such as Taltz, Xeljanz, and Orencia fall?<\/li>\n<li>What changes have taken place in the treatment algorithm within the last three years? What therapies have a growing or shrinking market share?\u00a0<\/li>\n<li>How compliant are\u00a0<abbr data-original-title=\"psoriatic arthritis\" title=\"\">PsA<\/abbr>\u00a0patients with their prescribed medication? What medications have the highest persistency?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390715","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390715\/revisions"}],"predecessor-version":[{"id":393839,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390715\/revisions\/393839"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}